Works matching DE "INTERFERON beta-1a"

Results: 263
    1
    2

    JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.

    Published in:
    Journal of Neuro-Oncology, 2018, v. 138, n. 3, p. 627, doi. 10.1007/s11060-018-2831-7
    By:
    • Wakabayashi, Toshihiko;
    • Natsume, Atsushi;
    • Mizusawa, Junki;
    • Katayama, Hiroshi;
    • Fukuda, Haruhiko;
    • Sumi, Minako;
    • Nishikawa, Ryo;
    • Narita, Yoshitaka;
    • Muragaki, Yoshihiro;
    • Maruyama, Takashi;
    • Ito, Tamio;
    • Beppu, Takaaki;
    • Nakamura, Hideo;
    • Kayama, Takamasa;
    • Sato, Shinya;
    • Nagane, Motoo;
    • Mishima, Kazuhiko;
    • Nakasu, Yoko;
    • Kurisu, Kaoru;
    • Yamasaki, Fumiyuki
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis.

    Published in:
    Annals of Clinical & Translational Neurology, 2022, v. 9, n. 7, p. 977, doi. 10.1002/acn3.51574
    By:
    • Fox, Robert J.;
    • Wiendl, Heinz;
    • Wolf, Christian;
    • De Stefano, Nicola;
    • Sellner, Johann;
    • Gryb, Viktoriia;
    • Rejdak, Konrad;
    • Bozhinov, Plamen Stoyanov;
    • Tomakh, Nataliya;
    • Skrypchenko, Iryna;
    • Muehler, Andreas R.
    Publication type:
    Article
    13
    14
    15
    16

    Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.

    Published in:
    BMC Pharmacology & Toxicology, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s40360-015-0025-x
    By:
    • Coenen, Martin;
    • Hinze, Annette Viktoria;
    • Mengel, Martin;
    • Fuhrmann, Christine;
    • Lüdenbach, Bastian;
    • Zimmermann, Julian;
    • Dykstra, Verena;
    • Fimmers, Rolf;
    • Viviani, Roberto;
    • Stingl, Julia;
    • Holdenrieder, Stefan;
    • Müller, Marcus;
    • Hartmann, Gunther;
    • Coch, Christoph
    Publication type:
    Article
    17
    18

    Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.

    Published in:
    Neurology & Therapy, 2021, v. 10, n. 2, p. 803, doi. 10.1007/s40120-021-00262-3
    By:
    • Hunter, Samuel F.;
    • Aburashed, Rany A.;
    • Alroughani, Raed;
    • Chan, Andrew;
    • Dive, Dominique;
    • Eichau, Sara;
    • Kantor, Daniel;
    • Kim, Ho Jin;
    • Lycke, Jan;
    • Macdonell, Richard A. L.;
    • Pozzilli, Carlo;
    • Scott, Thomas;
    • Sharrack, Basil;
    • Wiendl, Heinz;
    • Chung, Luke;
    • Daizadeh, Nadia;
    • Baker, Darren P.;
    • Vermersch, Patrick
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.

    Published in:
    2020
    By:
    • Ranieri, V. Marco;
    • Pettilä, Ville;
    • Karvonen, Matti K.;
    • Jalkanen, Juho;
    • Nightingale, Peter;
    • Brealey, David;
    • Mancebo, Jordi;
    • Ferrer, Ricard;
    • Mercat, Alain;
    • Patroniti, Nicolò;
    • Quintel, Michael;
    • Vincent, Jean-Louis;
    • Okkonen, Marjatta;
    • Meziani, Ferhat;
    • Bellani, Giacomo;
    • MacCallum, Niall;
    • Creteur, Jacques;
    • Kluge, Stefan;
    • Artigas-Raventos, Antonio;
    • Maksimow, Mikael
    Publication type:
    journal article
    28
    29
    30
    31
    32

    Erratum.

    Published in:
    European Neurology, 2023, v. 86, n. 6, p. 430, doi. 10.1159/000535278
    Publication type:
    Article
    33
    34
    35
    36
    37

    Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial.

    Published in:
    2017
    By:
    • Bellingan, Geoff;
    • Brealey, David;
    • Mancebo, Jordi;
    • Mercat, Alain;
    • Patroniti, Nicolò;
    • Pettilä, Ville;
    • Quintel, Michael;
    • Vincent, Jean-Louis;
    • Maksimow, Mikael;
    • Jalkanen, Markku;
    • Piippo, Ilse;
    • Ranieri, V. Marco
    Publication type:
    journal article
    38
    39
    40

    Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.

    Published in:
    BMC Neurology, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2377-14-114
    By:
    • Pecori, Chiara;
    • Giannini, Marta;
    • Portaccio, Emilio;
    • Ghezzi, Angelo;
    • Hakiki, Bahia;
    • Pastò, Luisa;
    • Razzolini, Lorenzo;
    • Sturchio, Andrea;
    • De Giglio, Laura;
    • Pozzilli, Carlo;
    • Paolicelli, Damiano;
    • Trojano, Maria;
    • Marrosu, Maria Giovanna;
    • Patti, Francesco;
    • Mancardi, Gian Luigi;
    • Solaro, Claudio;
    • Totaro, Rocco;
    • Tola, Maria Rosaria;
    • De Luca, Giovanna;
    • Lugaresi, Alessandra
    Publication type:
    Article
    41
    42
    43
    44
    45
    46

    Interferon beta 1a (Rebif®) in relapsing remitting multiple sclerosis.

    Published in:
    Drug Development Research, 2021, v. 82, n. 5, p. 707, doi. 10.1002/ddr.21798
    By:
    • Sánchez, Reinier Cardentey;
    • de la Fe, Amado Díaz;
    • Suarez, Alejandro Peláez;
    • Grass, Dayme;
    • Vega, Teresa Morgado;
    • Canal, Armando Sánchez;
    • Siniscalco, Dario;
    • de los Angeles Robinson Agramonte, María
    Publication type:
    Article
    47
    48
    49
    50